Clinical Trials

Burkitt Lymphoma, Leukemia

NCT06088290 2026-03-11

SaLuDo

450 enrolled

Sarcoma

Leiomyosarcoma, Neoplasms

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Phase 3 Not yet recruiting

Lymphoma, Follicular

NCT07286331 2026-03-11

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

600 enrolled

Endometrial Neoplasms

NCT07044336 2026-03-05

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

700 enrolled

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT04623541 2026-03-04

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04542824 2026-03-03

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-03-03

EPCORE™FL-2

1,095 enrolled

Phase 3 Not yet recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT05218499 2026-03-02

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 2/3 Completed

400 enrolled 15 charts

Sarcoma

Liposarcoma

NCT07441460 2026-03-02

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

1,800 enrolled

Resectable HER2-positive Breast Cancer

NCT01712490 2026-02-27

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

1,334 enrolled 23 charts

Hodgkin Disease, Lymphoma

NCT04008797 2026-02-27

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

GastrointestinalGynecologic

301 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled

Breast Neoplasms

NCT06960577 2026-02-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT05888493 2026-02-20

LEDA

109 enrolled

Phase 2 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2 Completed

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT06356129 2026-02-12

GOLSEEK-1

850 enrolled

Lymphoma

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Lymphoma, Follicular, Recurrence

NCT06091865 2026-02-05

OLYMPIA-3

904 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06564038 2026-02-05

Soundtrack-E

Phase 1/2 Recruiting

276 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04884035 2026-02-04

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1 Recruiting

174 enrolled

Lymphoma, B-Cell

NCT06340568 2026-02-02

Fern-EC-01

480 enrolled

Endometrial Neoplasms

NCT06486441 2026-01-15

ASCENT-GYN-01

640 enrolled

Endometrial Neoplasms

NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Phase 2 Terminated

71 enrolled

GynecologicSarcoma

Advanced Endometrial Cancer

NCT06132958 2026-01-09

TroFuse-005

710 enrolled

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Lymphoma, Lymphoma, Follicular

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast Neoplasms

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

468 enrolled

Ovarian Neoplasms

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

59 enrolled 63 charts

Hodgkin Disease

NCT06072131 2025-10-23

CRESCENDO

504 enrolled

Lymphoma, T-Cell, Peripheral

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Lymphoma, Follicular

NCT05630209 2025-10-02

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

Phase 1/2 Recruiting

10 enrolled

CNS

Brain Neoplasms

NCT06947967 2025-09-15

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

224 enrolled

Lymphoma, T-Cell, Peripheral

NCT04908787 2025-09-11

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

421 enrolled

Ovarian Neoplasms

NCT03860844 2025-09-09

ISAKIDS

Phase 2 Terminated

67 enrolled 25 charts

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04824092 2025-09-08

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Hodgkin Disease

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Phase 1/2 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07035379 2025-08-22

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

66 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07124936 2025-08-15

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Phase 1/2 Recruiting

97 enrolled